Document is current

Article History

Received: 2 November 2025

Accepted: 12 February 2026

First Online: 3 March 2026

Competing interests

: M.C.G.: Speaker fees and/or honoraria for consulting or advisory functions: Novartis, Knight Therapeutics, AstraZeneca, AbbVie, Daiichi-Sankyo, and GSK. Financial support for educational programs and symposia: AstraZeneca, AbbVie, Pfizer, and GSK. R.B.-S.: Speaker fees and/or honoraria for consulting or advisory functions: AstraZeneca, Daiichi-Sankyo, Eli Lilly, Gilead, Libbs, Pfizer, Novartis, MSD, and Roche. Financial support for educational programs and symposia: AstraZeneca, Daiichi-Sankyo, Gilead, Eli Lilly, and MSD. Institutional research grant: AstraZeneca, Daiichi-Sankyo. L.L.: Speaker fees and/or honoraria for consulting or advisory functions: Adium. Travel grants: MSD, Gador. L.T.: Speaker fees and/or honoraria for consulting or advisory functions: Daiichi-Sankyo, MSD, AstraZeneca, Pfizer, Lilly, and Novartis. Financial support for educational programs and symposia: AstraZeneca, Roche, and Gilead. Institutional research grant: Novartis. M.C.T.: Declares no conflict of interest. F.C.B.: Declares no conflict of interest. C.H.A.: Speaker fees and/or honoraria for consulting or advisory functions: Daiichi-Sankyo, Gilead, AstraZeneca, Novartis, and MSD. Financial support for educational programs and symposia: AstraZeneca, Daiichi-Sankyo, MSD, Lilly, Roche, Novartis, Gilead, and Medscape. D.M.G.: Speaker fees and/or honoraria for consulting or advisory functions: Daiichi-Sankyo, Teva, Roche, AstraZeneca, Pfizer, Lilly, and Novartis. Financial support for educational programs and symposia: AstraZeneca, Libbs, and Roche. Research grant: Novartis. M.L.B.: Speaker fees and/or honoraria for consulting or advisory functions: Daiichi Sankyo, Roche, Pfizer, Novartis, Lilly, AstraZeneca. G.C.: Speaker fees and/or honoraria for consulting or advisory functions: Amgen, AstraZeneca. Travel grants: Roche. D.A.-S.: Speaker fees and/or honoraria for consulting or advisory functions: Daiichi-Sankyo. Financial support for educational programs and symposia: AstraZeneca. D.D.R.: Speaker fees and/or honoraria for consulting or advisory functions: AstraZeneca, Daiichi-Sankyo, Lilly, Libbs, Pfizer, Novartis, Roche, GSK, Sanofi, Amgen, and Zodiac Pharma. Financial support for educational programs and symposia: Roche. N.J.B.G.: Participation in courses, symposia, lectures, and advisory boards for AstraZeneca, Daiichi-Sankyo, Gilead, Novartis, and Lilly. Declares no participation in sponsored clinical trials or continuous contracts/stock ownership in pharmaceutical companies. N.C.C.N.: Speaker fees and/or honoraria for consulting or advisory functions: AstraZeneca, Daiichi-Sankyo, Roche, Pfizer, Lilly, Novartis, and MSD. I.M.S.: Declares no conflict of interest. M.O.A.: Declares no conflict of interest. F.M.: Declares no conflict of interest. R.D.P.F.: Declares no conflict of interest. C.L.S.: Declares no conflict of interest. M.S.: Speaker fees and/or honoraria for consulting or advisory functions: Adium, GSK. Travel grants: Roche, AstraZeneca, MSD. M.R.M.: Speaker fees and/or honoraria for consulting or advisory functions: AstraZeneca, Daiichi-Sankyo, Pfizer, Novartis, Roche, MSD, and Knight. Financial support for educational programs and symposia: MSD, AstraZeneca, Knight, and Novartis. Z.S.S.: Declares no conflict of interest. A.M.U.G.: Declares no conflict of interest. B.M.Z.: Speaker fees and/or honoraria for consulting or advisory functions: AstraZeneca, Daiichi-Sankyo, Eli Lilly, Gilead, Pfizer, Novartis, MSD, Roche, and Adium. A.F.: Speaker fees and/or honoraria for consulting or advisory functions: Daiichi-Sankyo, Novartis, Gilead, MSD, BMS, AstraZeneca, and Pfizer. Financial support for educational programs and symposia: AstraZeneca, Daiichi-Sankyo, MSD, and Novartis. M.M.F.M.: Speaker fees and/or honoraria for consulting or advisory functions: AstraZeneca, Daiichi-Sankyo, Eli Lilly, Gilead, Adium, Novartis, MSD, and Roche. Financial support for educational programs and symposia: AstraZeneca, Daiichi-Sankyo, Gilead, Eli Lilly, Roche, MSD, and Novartis. P.A.S.: Speaker fees and/or honoraria for consulting or advisory functions: AstraZeneca, Eli Lilly, Pfizer, Novartis, Johnson & Johnson, Takeda, and Adium. S.S.: Declares no conflict of interest. P.M.H.: Speaker fees and/or honoraria for consulting or advisory functions: Daiichi-Sankyo. C.P.: Speaker fees and/or honoraria for consulting or advisory functions: Knight. Travel grants: AstraZeneca, Gador, Novartis, Pfizer, Raffo, and Roche. M.D.P.E.-D.: Declares no conflict of interest. R.C.B.: Speaker fees and/or honoraria for consulting or advisory functions: Daiichi-Sankyo, Nestlé Health Science, Adium, Gilead, MSD, BMS, AstraZeneca, Aché, Pfizer, Roche, Libbs, Lilly, Novartis, and GSK. Financial support for educational programs and symposia: AstraZeneca, Daiichi-Sankyo, and MSD. Institutional research grants: Novartis and AstraZeneca.